NCT07071103View on ClinicalTrials.gov

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2028

Conditions
Immune Checkpoint Inhibitor ResistanceRadiotherapyMetastatic Solid CancersImmune Checkpoint BlockadeEsophageal CancersLung Cancer
Interventions
RADIATION

Low-dose radiotherapy to the intestine (ILDR)

A single total dose of 1 Gy irradiation targeting the jejunum and ileum. Primary tumor or metastatic lesions that are within the irradiation field are irradiated concurrently.

DRUG

PD-1/PD-L1 monoclonal antibodies

Pre-progression immunotherapy regimen continues or switches to an alternative PD-1/PD-L1 monoclonal antibody according to clinical guidelines.PD-1/PD-L1 monoclonal antibody will be given 1 day after ILDR at a 3-week interval.

Trial Locations (1)

515031

RECRUITING

Cancer Hospital, Shantou University Medical College, Shantou

All Listed Sponsors
lead

Chuangzhen Chen

OTHER